EGFR and neoplasm: LUAD is characterized by distinct oncogenic mutations (such as EGFR mutations) that co‐occur with many tumor suppressor gene alterations, which could alter the way SNRPA interacts with cellular machinery.[53] Additionally, the tumor microenvironment in LUAD, with its specific extracellular matrix components and signaling molecules, might also contribute to this differential regulation.[54]